Collaborations & Alliances
Related Searches:
Filter by:
796 - 810 of 1104 results
November 11, 2008
BioBlocks, Inc. and outsourcing partner, MannKind Corp., will continue their lead optimization collaboration. The two companies have worked together since January 2007, and have met milestones utilizing BioBlocks' expertise in medicinal chemistry and…
Read More »
November 10, 2008
WuXi PharmaTech has signed a new three-year, in vitro ADME collaboration agreement with Pfizer. The companies will establish ADME assays to provide in vitro screening services on compounds WuXi PharmaTech synthesizes for Pfizer. The evaluation of ADM…
Read More »
November 10, 2008
ArQule, Inc. and Daiichi Sankyo Co., Ltd. have entered into two agreements forming a strategic relationship for the development and discovery of new oncology therapeutics.
The two companies will co-develop ARQ 197, an orally adm…
Read More »
October 24, 2008
GlaxoSmithKline Biologicals (a GSK unit) and AFFiRiS GmbH have entered a collaboration agreement granting GSK exclusive rights to AFFiRiS's Alzheimer's disease vaccine programs that target beta-amyloid. GSK is acquiring exclusive rights to develop an…
Read More »
October 17, 2008
Valeant Pharmaceuticals International has concluded its exclusive worldwide collaboration agreement with GlaxoSmithKline for retigabine, an investigational drug for the treatment of adult epilepsy patients with refractory partial onset seizures. Unde…
Read More »
October 16, 2008
WuXi PharmaTech, Inc. has reached an agreement with Johnson & Johnson Pharmaceutical R&D, Division of Janssen Pharmaceutica, N.V. (J&JPRD) to expand its pharmaceutical R&D services collaboration. In addition to providing discovery che…
Read More »
October 13, 2008
Genmab has reached the sixth milestone in its collaboration with GlaxoSmithKline for ofatumumab (HuMax-CD20), as the first patient received treatment in the Phase I study of ofatumumab in relapsed/refractory follicular non-Hodgkin's lymphoma and chro…
Read More »
October 7, 2008
Alnylam Pharmaceuticals has earned a $20 million technology transfer milestone from Takeda Pharmaceutical Co. Ltd. as part of the companies' strategic alliance formed in May 2008. The payment is related to the transfer of Alnylam’s platform tec…
Read More »
October 3, 2008
Genentech, Roche, and GlycArt (a company wholly-owned by Roche) have entered into a collaboration that includes a license from GlycArt to Genentech for the joint development and commercialization of GlycArt’s GA101 molecule. The companies will…
Read More »
September 25, 2008
Lonza and Crucell have entered into a co-exclusive manufacturing, sales and distribution agreement related to the Permexcis cell culture medium developed by Crucell for PER.C6 cells. Under this agreement, Lonza will manufacture the medium, and in add…
Read More »
September 25, 2008
Merck and Japan Tobacco Inc. (JT) have signed a worldwide licensing agreement to develop and commercialize JTT-305, an investigational oral osteoanabolic (bone growth stimulating) agent for the treatment of osteoporosis.
Merck will gain worldwide…
Read More »
September 19, 2008
MethylGene, Inc. has exercised its right to convert to a royalty and milestone arrangement with Celgene Corp. for MGCD0103 under the 2006 license and collaboration agreement between the companies.
MethylGene will no longer be re…
Read More »
September 12, 2008
MedImmune, the global biologics unit of AstraZeneca, and SBI Biotech Co., Ltd, have entered into a licensing and collaboration agreement to develop and commercialize SBI Biotech's anti-ILT7 protein for the potential treatment of systemic lupus erythe…
Read More »
September 10, 2008
Cellzome, Inc. and GlaxoSmithKline entered a worldwide strategic alliance to discover, develop and market novel kinase-targeted therapeutics to treat inflammatory diseases. The alliance gives GSK access to Cellzome's expertise in identifying and deve…
Read More »
September 4, 2008
Merck Serono has entered into an agreement with Ablynx to discover and develop Nanobodies against two targets in oncology and immunology. The agreement includes an upfront cash payment to Ablynx of $14.5 million.
Nanobodie…
Read More »
796 - 810 of 1104 results
